Promoted Content
Promoted Content

Find Approved Dermatology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothA partner for the pharma and biotech industries to improve patient outcomes & quality of life

            Contact the Supplier

            Lead Product(s): Clascoterone

            Therapeutic Area: Dermatology Product Name: Winlevi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cassiopea

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 04, 2020

            Details:

            Albany Molecular Research has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azeloglycine

            Therapeutic Area: Dermatology Product Name: Iwostin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Perrigo Company plc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition November 02, 2020

            Details:

            Perrigo has completed the acquisition of three Eastern European OTC skincare and hair loss treatment brands, Emolium®, Iwostin® and Loxon® from Sanofi. The acquisition has opened door for Perrigo's transformation to a consumer-focused, global self-care company.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azeloglycine

            Therapeutic Area: Dermatology Product Name: Iwostin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Perrigo Company plc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 11, 2020

            Details:

            Perrigo will acquire three Eastern European OTC skincare and hair loss treatment brands (Emolium®, Iwostin® and Loxon®) from Sanofi.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dupilumab

            Therapeutic Area: Dermatology Product Name: Dupixent

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2020

            Details:

            Recommendation was supported by multiple clinical trials that demonstrated superiority of Dupixent® over placebo in improving disease extent and severity, skin clearance and itch intensity, as well as health-related quality of life.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Tetracaine

            Therapeutic Area: Dermatology Product Name: Pliaglis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Juyou Biotechnology

            Deal Size: $2.9 million Upfront Cash: $0.1 million

            Deal Type: Licensing Agreement November 05, 2020

            Details:

            Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Baricitinib

            Therapeutic Area: Dermatology Product Name: Olumiant

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Incyte Corporation

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 31, 2020

            Details:

            New data for baricitinib for the treatment of moderate to severe atopic dermatitis showed that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ixekizumab

            Therapeutic Area: Dermatology Product Name: Taltz

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Taltz demonstrated sustained efficacy in adult psoriasis patients with baseline scalp, nail and palmoplantar (skin on the palms of the hands and soles of the feet) involvement with the following results at five years.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dupilumab

            Therapeutic Area: Dermatology Product Name: Dupixent

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Presentations include data from open-label extension trials evaluating laboratory assessments in adults treated with Dupixent for up to three years and adolescents (aged 12 to 17 years) treated up to one year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Calcipotriol,Betamethasone Dipropionate

            Therapeutic Area: Dermatology Product Name: Enstilar

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            U.S. Prescribing Information (USPI) updated to include PSO-LONG clinical trial data concerning long-term use (52 weeks) of twice-weekly topical treatment with Enstilar® (calcipotriene and betamethasone dipropionate) Foam in adults with plaque psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dupilumab

            Therapeutic Area: Dermatology Product Name: Dupixent

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            Recommendation based on pivotal trial that showed Dupixent plus topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearance, itch and health-related quality of life, compared to TCS alone .

            PharmaCompass